Legend Biotech (LEGN) is back in focus after reporting five year follow up data from its CARTITUDE 2 Cohort A study of CARVYKTI in relapsed or refractory multiple myeloma.
Legend Biotech’s latest CARVYKTI update lands after a tough run for holders, with the share price down 33.83% over 90 days and the 1 year total shareholder return falling 41.83%. At the same time, the past week’s 3.13% share price return hints at stabilising short term momentum against a longer track record of weaker total shareholder returns over 3 and 5 years.
Spot 16 high quality undiscovered gems that, like Legend Biotech after this CARVYKTI update, combine complex pipelines with stories that the wider market may not be fully pricing in yet.Legend Biotech now trades around US$19 after a steep slide and a brief bounce. Does that reset create a reasonable entry today, or does it argue for patience until expectations and price move closer together?
Most Popular Narrative: 61% Undervalued
Legend Biotech’s most followed valuation narrative places fair value at $49.25 against a last close of $19.11. This frames the current pullback as a wide gap between price and modeled fundamentals discounted at 7.51% a year.
Significant expansion potential in both earlier lines of therapy and frontline settings for multiple myeloma, driven by strong survival data, ongoing clinical trials (CARTITUDE 5 and 6), and label updates that increase patient access, is setting up long term revenue acceleration as the patient pool widens.
See why 25 investors see Legend Biotech as 61% undervalued.
Result: Fair Value of $49.25 (UNDERVALUED)
Still, the Legend Biotech narrative can unravel quickly if CARVYKTI underperforms expectations or if high research spending keeps profitability out of reach for longer than hoped.
Find out about the key risks to this Legend Biotech narrative.
Next Steps
If this mix of optimism and caution around Legend Biotech leaves you on the fence, move quickly to test the thesis against your own research. Start by weighing the 4 key rewards.
Looking for more Legend Biotech style investment ideas?
If Legend Biotech has sharpened your appetite for differentiated stories, do not stop here. Use the screener tools to spot other opportunities before the crowd does.
- Target potential mispricings by scanning for companies with strong fundamentals that trade below modeled value through the 32 high quality undervalued stocks.
- Protect your downside by focusing on resilient businesses with cleaner finances using the 30 resilient stocks with low risk scores.
- Hunt for future standouts that are still off most radars by checking the 16 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com